These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22626604)

  • 1. Acute hemolysis secondary to high-dose intravenous immunoglobulin in a patient with Stevens-Johnson syndrome.
    Shakouri AA; Bahna SL
    Ann Allergy Asthma Immunol; 2012 Jun; 108(6):463-4. PubMed ID: 22626604
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous immunoglobulin-induced hemolytic anemia in a patient with juvenile dermatomyositis.
    Clemenz MR; McGowan Iv JW; Shuler MJ; Lynn AW
    J Drugs Dermatol; 2013 Jan; 12(1):111-3. PubMed ID: 23377338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of intravenous high-dose immunoglobulins (IGIV) in a case of Stevens-Johnson syndrome].
    Amato GM; Travia A; Ziino O
    Pediatr Med Chir; 1992; 14(5):555-6. PubMed ID: 1488317
    [No Abstract]   [Full Text] [Related]  

  • 4. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.
    Letko E; Papaliodis DN; Papaliodis GN; Daoud YJ; Ahmed AR; Foster CS
    Ann Allergy Asthma Immunol; 2005 Apr; 94(4):419-36; quiz 436-8, 456. PubMed ID: 15875523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy.
    Mohamed M; Bates G; Eastley B
    Br J Haematol; 2013 Mar; 160(5):570. PubMed ID: 23294261
    [No Abstract]   [Full Text] [Related]  

  • 6. Non-drug-induced Stevens-Johnson syndrome successfully treated with high-dose i.v. immunoglobulin.
    Nozaki Y; Fujita H; Okada R; Kou K; Aihara M
    J Dermatol; 2015 Apr; 42(4):439-40. PubMed ID: 25753003
    [No Abstract]   [Full Text] [Related]  

  • 7. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Yeung CK; Lam LK; Chan HH
    Clin Exp Dermatol; 2005 Sep; 30(5):600-2. PubMed ID: 16045716
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of intravenous immunoglobulin administration on erythrocyte and leucocyte parameters.
    Cicha A; Fischer MB; Wesinger A; Haas S; Bauer WM; Wolf HM; Sauerwein KMT; Reininger B; Petzelbauer P; Pehamberger H; Handisurya A
    J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):1004-1010. PubMed ID: 29114967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome.
    Hebert AA; Bogle MA
    J Am Acad Dermatol; 2004 Feb; 50(2):286-8. PubMed ID: 14726889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular eczema after intravenous immunoglobulin therapy for treatment of Stevens-Johnson syndrome.
    Young PK; Ruggeri SY; Galbraith S; Drolet BA
    Arch Dermatol; 2006 Feb; 142(2):247-8. PubMed ID: 16490861
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravenous immunoglobulin therapy for Stevens-Johnson syndrome.
    Brett AS; Philips D; Lynn AW
    South Med J; 2001 Mar; 94(3):342-3. PubMed ID: 11284525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin.
    Gordon DJ; Sloan SR; de Jong JL
    Am J Hematol; 2009 Nov; 84(11):771-2. PubMed ID: 19806664
    [No Abstract]   [Full Text] [Related]  

  • 13. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis.
    Stella M; Clemente A; Bollero D; Risso D; Dalmasso P
    Burns; 2007 Jun; 33(4):452-9. PubMed ID: 17475410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose i.v. 7S immunoglobulin treatment in Stevens-Johnson syndrome.
    Cazzola G; Nicolussi M; Carraro F; Cavalieri S; Graziani MS
    Helv Paediatr Acta; 1986 May; 41(1-2):87-8. PubMed ID: 3721900
    [No Abstract]   [Full Text] [Related]  

  • 15. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Fromowitz JS; Ramos-Caro FA; Flowers FP;
    Int J Dermatol; 2007 Oct; 46(10):1092-4. PubMed ID: 17910723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options.
    Teo L; Tay YK; Liu TT; Kwok C
    Singapore Med J; 2009 Jan; 50(1):29-33. PubMed ID: 19224081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Onset of Anemia After IV Immunoglobulin.
    Gradidge E; Rodwig F; Warrier R
    Clin Pediatr (Phila); 2016 Jun; 55(6):572-3. PubMed ID: 26611894
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravenous immunoglobulin-induced, non-eczematous, vesiculobullous eruptions in Stevens-Johnson syndrome.
    Lin WL; Lin WC; Chang YC; Yang LC; Hung SI; Hong HS; Chung WH
    Am J Clin Dermatol; 2009; 10(5):339-42. PubMed ID: 19658448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders.
    Markvardsen LH; Christiansen I; Harbo T; Jakobsen J
    Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous Immunoglobulin-Associated Hemolytic Anemia.
    Jacobs J; Kneib J; Gabbard A
    Lab Med; 2020 Sep; 51(5):e47-e50. PubMed ID: 32339244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.